Kevin D Courtney

  • 1691 Citations
  • 13 h-Index
19982019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 4 Similar Profiles
Renal Cell Carcinoma Medicine & Life Sciences
Prostatic Neoplasms Medicine & Life Sciences
Castration Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Phosphatidylinositol 3-Kinase Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Phosphatidylinositols Medicine & Life Sciences
Radiotherapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2019

  • 1691 Citations
  • 13 h-Index
  • 24 Article
  • 1 Chapter
1 Citations
T-Lymphocytes
Antibodies
Neoplasms
Colonic Neoplasms
Colorectal Neoplasms
2 Citations

Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo

Courtney, K. D., Bezwada, D., Mashimo, T., Pichumani, K., Vemireddy, V., Funk, A. M., Wimberly, J., McNeil, S. S., Kapur, P., Lotan, Y., Margulis, V., Cadeddu, J. A., Pedrosa, I., DeBerardinis, R. J., Malloy, C. R., Bachoo, R. & Maher, E. A., Nov 6 2018, In : Cell metabolism. 28, 5, p. 793-800.e2

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Isotopes
Citric Acid Cycle
Glucose
Neoplasms

MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG

Fets, L., Driscoll, P. C., Grimm, F., Jain, A., Nunes, P. M., Gounis, M., Doglioni, G., Papageorgiou, G., Ragan, T. J., Campos, S., Silva dos Santos, M., MacRae, J. I., O’Reilly, N., Wright, A. J., Benes, C. H., Courtney, K. D., House, D. & Anastasiou, D., Nov 1 2018, In : Nature chemical biology. 14, 11, p. 1032-1042 11 p.

Research output: Contribution to journalArticle

Glutamine
Glutamate Dehydrogenase
Citric Acid Cycle
Prodrugs
Metabolic Networks and Pathways
22 Citations

Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2a antagonist in patients with previously treated advanced clear cell renal cell carcinoma

Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J. B., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., Josey, J. A. & Choueiri, T. K., Jan 1 2018, In : Journal of Clinical Oncology. 36, 9, p. 867-874 8 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Safety
Pharmacokinetics
Hypoxia
Therapeutics
1 Citations

Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy

Mohamad, O., Diaz De Leon III, A., Schroeder, S., Leiker, A., Christie, A., Zhang-Velten, E., Trivedi, L., Khan, S., Desai, N. B., Laine, A. M., Albuquerque, K., Iyengar, P., Arriaga, Y. E., Courtney, K. D., Gerber, D. E., Hammers, H., Choy, H., Timmerman, R., Brugarolas, J. B. & Hannan, R., Mar 10 2018, (Accepted/In press) In : OncoImmunology.

Research output: Contribution to journalArticle

Radiotherapy
Safety
Disease-Free Survival
Fatigue
Melanoma